Kennedy Capital Management LLC Sells 41,495 Shares of Accuray Incorporated (NASDAQ:ARAY)

Kennedy Capital Management LLC cut its holdings in Accuray Incorporated (NASDAQ:ARAY) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 723,438 shares of the medical equipment provider’s stock after selling 41,495 shares during the period. Kennedy Capital Management LLC owned about 0.70% of Accuray worth $1,432,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ARAY. Prudential Financial Inc. purchased a new position in Accuray in the fourth quarter worth about $43,000. SG Americas Securities LLC increased its position in shares of Accuray by 37.4% during the 4th quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 12,259 shares during the last quarter. Intech Investment Management LLC raised its holdings in Accuray by 104.1% during the 4th quarter. Intech Investment Management LLC now owns 46,680 shares of the medical equipment provider’s stock valued at $92,000 after buying an additional 23,808 shares during the period. Perkins Capital Management Inc. lifted its position in Accuray by 18.3% in the fourth quarter. Perkins Capital Management Inc. now owns 68,000 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 10,500 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Accuray during the third quarter worth $244,000. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Accuray from a “hold” rating to a “buy” rating in a research note on Friday.

Accuray Stock Up 3.4 %

Shares of NASDAQ ARAY opened at $1.51 on Tuesday. The company has a market cap of $155.27 million, a P/E ratio of -30.20 and a beta of 1.30. The firm has a 50-day simple moving average of $1.91 and a two-hundred day simple moving average of $1.96. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $2.95. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. Research analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.